Development of a μO-conotoxin analogue with improved lipid membrane interactions and potency for the analgesic sodium channel NaV1.8

37Citations
Citations of this article
37Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The μO-conotoxins MrVIA, MrVIB, and MfVIA inhibit the voltage-gated sodium channel NaV1.8, a well described target for the treatment of pain; however, little is known about the residues or structural elements that define this activity. In this study, we determined the three-dimensional structure of MfVIA, examined its membrane binding properties, performed alanine-scanning mutagenesis, and identified residues important for its activity at human NaV1.8. A second round of mutations resulted in (E5K,E8K)MfVIA, a double mutant with greater positive surface charge and greater affinity for lipid membranes compared with MfVIA. This analogue had increased potency at NaV1.8 and was analgesic in the mouse formalin assay.

Cite

CITATION STYLE

APA

Deuis, J. R., Dekan, Z., Inserra, M. C., Lee, T. H., Aguilar, M. I., Craik, D. J., … Vetter, I. (2016). Development of a μO-conotoxin analogue with improved lipid membrane interactions and potency for the analgesic sodium channel NaV1.8. Journal of Biological Chemistry, 291(22), 11829–11842. https://doi.org/10.1074/jbc.M116.721662

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free